Core Viewpoint - The recent application of long-acting HIV pre-exposure prophylaxis (PrEP) drug Lenacapavir in Boao provides a new option for individuals in need, requiring only two doses per year for HIV protection [1] Group 1: Product Overview - Lenacapavir is an HIV-1 capsid inhibitor that effectively reduces the risk of HIV-1 transmission through sexual activity, marking a significant advancement in HIV-1 prevention [1] - The drug is suitable for adults and adolescents weighing at least 35 kg who are at risk of HIV-1 infection, provided they are HIV-1 negative before starting treatment [1] Group 2: Administration and Convenience - Lenacapavir offers a dual formulation approach: the injection form requires administration only twice a year (once every six months), while the oral tablets provide a flexible option for quick intervention [1] - The subcutaneous injection method enhances medication convenience and adherence, particularly for individuals who struggle with daily medication regimens [1]